S everal decades ago, the concept of pharmacogenomics was something akin to fantasy or science fiction. Now, however, it is becoming more important each year. During November 2003, the concept took an important first step toward practical application and acceptance by the medical community.
This small step was comparable in importance to the first steps that man made on the moon during July 1969 and, similarly, can be characterized by US astronaut Neil Armstrong's famous words from the lunar surface:
"That's one small step for man, one giant leap for mankind."
So what was this small step? The FDA issued a draft document, "Guidance for Industry: Pharmacogenomic Data Submissions." 1 The potential of pharmacogenomic data in medicine is not fully understood, but its potential application to drug development and individualized patient therapy -based on the patient's genetic code -is unlimited.
An example of such an advance is trastuzumab, a treat-ment for metastatic breast cancer in women who overexpress human epidermal growth factor receptor-2 (HER2). This agent was developed using knowledge about the role of HER2 in breast cancer and the application of pharmacogenomic drug data.
The issuance of the FDA guidance document placed pharmacogenomics in a position where it can begin to grow to a fully realized discipline.While the document was only a draft intended for review and discussion, it represented a clear indication that the FDA is dedicated to the promotion of the best science. It should also increase the public's confidence in the application of pharmacogenomic principles in drug development and application.
Concepts addressed in this draft guidance document were: • General principles related to pharmacogenomics • Specific uses of pharmacogenomic data in drug development and labeling • Voluntary submission of exploratory pharmacogenomic research data • Process for submission of phar-macogenomic data • FDA review of pharmacogenomic data We can only hope that during the next decade we revisit this issue several more times and that each time our review is associated with improvements in the safety and efficacy of medications as a result of the application of pharmacogenomics in the drug development process.
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